Prostate cancer imaging of FSHR antagonist modified with a hydrophilic linker

In conclusion, 18F‐Al‐NOTA‐MAL‐FSH2 was successfully prepared in a one‐step method and showed better pharmacokinetics than 18F‐Al‐NOTA‐MAL‐FSH1. Favorable preclinical study revealed that 18F‐Al‐NOTA‐MAL‐FSH2 appears to be a promising candidate for FSHR‐positive tumor imaging. Copyright © 2015 John Wiley & Sons, Ltd.

GGGRDN‐modified FSH1 reduced the liver accumulation and optimized the abdominal background visualized by microPET.

Source: Contrast Media and Molecular Imaging - July 1, 2015 Category: Radiology Authors: Chen Zhu, Qing Xu, Donghui Pan, Yuping Xu, Ping Liu, Runlin Yang, Lizhen Wang, Xinchen Sun, Shineng Luo, Min Yang Tags: Full paper Source Type: research